Trial Profile
A Randomised, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PIROUETTE
- 01 Jul 2023 Results assessing treatment adherence through pill counts and diary cards, published in the Journal of Cardiac Failure.
- 01 Aug 2021 Primary endpoint has been met. (Extracellular volume fraction (ECV), as per Results published in the Nature Medicine
- 01 Aug 2021 Results published in the Nature Medicine